Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) issued its earnings results on Monday. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.01), MarketWatch Earnings reports. Marinus Pharmaceuticals had a negative return on equity of 86.10% and a negative net margin of 572.12%. During the […]
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) announced its earnings results on Monday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01), MarketWatch Earnings reports. Marinus Pharmaceuticals had a negative net margin of 572.12% and a negative return on equity of 86.10%. During the same […]
StockNews.com lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Other research analysts have also recently issued research reports about the company. JMP Securities reissued a buy rating and issued a $23.00 price objective on shares of Marinus Pharmaceuticals in […]
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price objective lifted by investment analysts at JMP Securities from $21.00 to $22.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target suggests a potential upside of 151.72% from the […]